IDEAYA Biosciences, Inc. (IDYA)

NMS – Real Time Price. Currency in USD

36.74

+0.45 (1.24%)

At close: Jun 26, 2026, 4:00 PM EDT

36.00

-0.74 (-2.01%)

After-hours: Jun 26, 2026, 6:30 PM EDT

17.06.2026

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

SOUTH SAN FRANCISCO, Calif., June 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that its Board of Directors has elected Yujiro S.

15.06.2026

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties IDE892 has a CYP3A4 IC50 greater than 45 micromolar, and did not show time dependent inhibition of any of the 7 major cytochrome P450s (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) based on full kinetic CYP inactivation assays IDE892 monotherapy Phase 1 escalation has cleared multiple dose cohorts with maximally efficacious target exposures anticipated at a favorable pill size and the MTD has not yet been reached. IDE892 monotherapy expansion is anticipated in Q3 2026 MTAP-deletion is estimated to occur in up to 40% of pancreatic cancer and ~15% of non-small cell lung cancer (NSCLC) SOUTH SAN FRANCISCO, Calif.

11.06.2026

Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026

IDEAYA Biosciences maintains a "Strong Buy" rating, driven by positive darovasertib data in uveal melanoma and robust clinical progress. The company's darovasertib + crizotinib met the mPFS primary endpoint in 1st-line HLA*A2-negative mUM, supporting an RTOR NDA Accelerated Approval submission filing. Upcoming catalysts include NDA filing submission completion of darovasertib in H2 2026, label expansion data for HLA*A2-positive mUM, and further neoadjuvant/adjuvant melanoma updates.

10.06.2026

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., June 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common stock at a public offering price of $27.00 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 5,555,576 shares of common stock at a public offering price of $26.9999 per pre-funded warrant, before underwriting discounts and commissions.

09.06.2026

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants.

08.06.2026

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering.

03.06.2026

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma IDEAYA will sponsor the clinical trial, and there will be joint IDEAYA and Roche governance to oversee the study MTAP-deletion is estimated to occur in up to 40% of PDAC SOUTH SAN FRANCISCO, Calif., June 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration with Roche to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class PRMT5 inhibitor, in combination with Roche's RG6505, a pan-RAS inhibitor, in patients with pancreatic ductal adenocarcinoma (PDAC) that carry an MTAP deletion.

Videos

No Data

There is no data to display

Press releases

17.06.2026

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

15.06.2026

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

10.06.2026

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

09.06.2026

IDEAYA Biosciences, Inc. (IDYA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

IDEAYA Biosciences, Inc. (IDYA)

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

Videos

No Data

Press releases

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

Videos

No Data

Press releases

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

Search stocks

IDEAYA Biosciences, Inc. (IDYA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

IDEAYA Biosciences, Inc. (IDYA)

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

Videos

No Data

Press releases

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

Videos

No Data

Press releases

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants